Weisbrod formed his new venture, Iguana Healthcare Partners, in the fall of 2009 and launched a long/short fund on January 1. The fund invests in biotechnology, pharmaceuticals, medical devices, health care services, and other health care sectors.
Weisbrod made his name as a securities analyst at Prudential-Bache Securities and later at Merrill Lynch before joining the buy side as a partner at Harpel Advisors and then at Oracle Partners.
